- Home
- AGMH vs JAGX Comparison
AGMH vs JAGX Comparison
Compare AGMH & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- JAGX
- Stock Information
- Founded
- AGMH 2015
- JAGX 2013
- Country
- AGMH Hong Kong
- JAGX United States
- Employees
- AGMH N/A
- JAGX N/A
- Industry
- AGMH EDP Services
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- AGMH Technology
- JAGX Health Care
- Exchange
- AGMH Nasdaq
- JAGX Nasdaq
- Market Cap
- AGMH 3.9M
- JAGX 3.9M
- IPO Year
- AGMH 2018
- JAGX N/A
- Fundamental
- Price
- AGMH $2.33
- JAGX $1.96
- Analyst Decision
- AGMH
- JAGX Strong Buy
- Analyst Count
- AGMH 0
- JAGX 1
- Target Price
- AGMH N/A
- JAGX $60.00
- AVG Volume (30 Days)
- AGMH 734.4K
- JAGX 143.5K
- Earning Date
- AGMH 05-13-2025
- JAGX 11-12-2025
- Dividend Yield
- AGMH N/A
- JAGX N/A
- EPS Growth
- AGMH N/A
- JAGX N/A
- EPS
- AGMH 6.43
- JAGX N/A
- Revenue
- AGMH $32,044,575.00
- JAGX $11,810,000.00
- Revenue This Year
- AGMH N/A
- JAGX $22.41
- Revenue Next Year
- AGMH N/A
- JAGX $30.00
- P/E Ratio
- AGMH $0.33
- JAGX N/A
- Revenue Growth
- AGMH N/A
- JAGX 15.96
- 52 Week Low
- AGMH $1.09
- JAGX $1.57
- 52 Week High
- AGMH $109.50
- JAGX $35.25
- Technical
- Relative Strength Index (RSI)
- AGMH 54.83
- JAGX 48.98
- Support Level
- AGMH $1.92
- JAGX $1.60
- Resistance Level
- AGMH $4.38
- JAGX $2.16
- Average True Range (ATR)
- AGMH 0.47
- JAGX 0.12
- MACD
- AGMH 0.04
- JAGX 0.06
- Stochastic Oscillator
- AGMH 28.82
- JAGX 66.10
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an integrated technology company. The company focuses on blockchain-oriented ASIC chip design, high-end crypto miner production, and fintech technology software services. The company generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.